Keywords: HLA-G; human leukocyte antigen G; HLA-E; human leukocyte antigen E; PD-L1; programmed cell death 1 ligand 1; IL-10; interleukin-10; TGF-β; transforming growth factor beta; sHLA-G; soluble HLA-G; OL; oral leukoplakia; GB; granzyme B; OPL; oral precancerou
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CTLA-4; cytotoxic T-lymphocyte-associated protein 4; ICI; immune checkpoint inhibitor; irAE; immune-related adverse event; mRSS; modified Rodnan skin score; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; RNAP3; RNA polymerase III;
Keywords: EMG; electromyographic examination; IV; intravenous; MRI; magnetic resonance imaging; NCS; nerve conduction study; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; PET; positron emission tomography;
Keywords: Acute pneumonitis; Afatinib; Anti PD-1 antibody; Immune checkpoint inhibitor; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; PD-1; programmed cell death-1; PD-L1; programmed cell death ligand-1; NSCLC; non-small cell lung cancer; BA
Keywords: Renal cell carcinoma; Tyrosine kinase inhibitor; PD-1; PD-L1; PD-L2;
Keywords: bsAb; bispecific antibody; CAR; chimeric antigen receptor; CDN; cyclic dinucleotides; CTL; cytotoxic T lymphocyte; CTLA-4; cytotoxic T-lymphocyte-associated protein 4; GM-CSF; granulocyte-monocyte colony stimulating factor; IR; irradiation; PD-1; Programm
Keywords: Mesothelioma; Immune-checkpoint; Immunotherapy; CTLA-4; PD-1; PD-L1;
Keywords: Testicular cancer; Germ cell cancer; PD-1; PD-L1; Checkpoint inhibition; Platinum refractory disease; Immunotherapy;
Keywords: adenocarcinoma; ALK; EGFR; molecular pathology; non-small cell lung cancer; pathology; PD-L1; ROS1;
Keywords: CT; computed tomography; C/T; consolidation/tumor; EGFR; epidermal growth factor receptor; GGO; ground-glass opacity; NSCLC; non-small cell lung cancer; PD-1; programmed death 1; PD-L1; programmed death ligand 1; SUVmax; maximum standardized uptake value;
Keywords: EGFR; Epidermal growth factor receptor; TP53; Tumor protein p53; KRAS; Kirsten rat carcoma viral oncogene; ALK; Anaplastic lymphoma kinase; RTK; Protein receptor tyrosine kinase; TKI; Tyrosine kinase inhibitor; PI3K; Phosphatidylinositol 3-kinase; NSCLC;
Keywords: CIK; cytokine-induced killer cells; PA-MSHA; Pseudomonas aeruginosa-mannose sensitive hemagglutinin; TILs; tumor-infiltrating lymphocytes; NK; natural killer cell; PD-L1; programmed death receptor ligand 1; DCs; dendritic cells; PRs; partial remissions; S
Keywords: CTLA-4; Immunotherapy; PD-1; PD-L1; Small-cell lung cancer;
Keywords: Melanoma; Programmed cell death-1; PD-L1; Ipilimumab-refractory; Survival;
Keywords: PSK; Gastric cancer; PD-L1; Natural killer cell; Prognosis;
Keywords: Non-small cell lung cancer; Vaccines; Immune checkpoint inhibitors; PD-L1;
Keywords: Lymphoid neoplasms; PD-1; PD-L1; PD-L2; Immune checkpoint;
Keywords: TME; tumour microenvironment; PD-1; programmed cell death 1; PD-L1; programmed death ligand 1; PD-L2; programmed death ligand 2; PTMs; post-translational histone modifications; DNMTi; DNA methyltransferase inhibitor; HDACi; histone deacetylase inhibitor;
Keywords: CAR; chimeric antigen receptor; Treg; regulatory T cell; PD-1; programmed death-1; CTLA-4; cytotoxic T-lymphocyte-associated protein 4; PD-L1; programmed death ligand 1; APC; antigen-presenting cell; DC; dendritic cell; TLR; toll-like receptor; OVA; ovalb
Keywords: ADCC; antibody-dependent cell-mediated cytotoxicity; AKT; protein kinase B; ATP; adenosine triphosphate; cfDNA; circulating free DNA; CISH; chromogenic in-situ hybridization; CTC; circulating tumor cells; EGFR; epithelial growth factor receptor; EMT; epit
Keywords: Immune Checkpoint; Virtual Microdissection; Molecular Subgroups; Immune Regulation; CCL; chemokine (C-C motif) ligand; CTNNB1; catenin beta 1; CXCL; chemokine (C-X-C motif) ligand; FDR; false discovery rate; FF; fresh frozen; FFPE; formalin-fixed paraffin
Keywords: Adenocarcinoma; Squamous cell carcinoma; Gastric; Esophageal; Immunotherapy; Immune checkpoint; PD-1; PD-L1;
Keywords: ABC; ATP-binding cassette; EGF; epidermal growth factor; EMT; epithelial-to-mesenchymal transition; IGF; insulin growth; MET; mesenchymal-to-epithelial transition; MMP; matrix metalloprotease; PD-L1; programmed death ligand 1; PDGFR-A; platelet-derived gr
Keywords: MDSC; Myeloid-derived suppressor cells; T-cell suppression; Checkpoints; PD-L1; PD-1;
Keywords: CT; Lung adenocarcinoma; PD-L1;
Keywords: PD-L1; FOXP3; CD8; Penile cancer; Squamous cell carcinoma; Immune checkpoint;
Keywords: AML; acute myeloid leukemia; BRCA; breast cancer; BRCC3; BRCA1/BRCA2-Containing Complex Subunit 3; C; constant; CLL; chronic lymphocytic leukemia; CML; chronic myeloid leukemia; CSC; cancer stem-like cell; EGFR; epidermal growth factor receptor; EMT; epit
Keywords: Lung cancer; Adenocarcinoma; Squamous cell carcinoma; Immune response; PD-L1; Gene expression;
Keywords: Biomarkers; Checkpoint molecules; Cytokines; Glioblastoma; Immunotherapy; Microbiome; Mutational landscape; CB; Cintredekin besudotox; CNS; Central nervous system; CTLA-4; Cytotoxic T lymphocyte antigen 4; CyTOF; Cytometry by time-of-flight; EGFR; Epiderm
Keywords: AFP; Alpha-fetoprotein; ANAs; Antinuclear antibodies; APCs; Antigen presenting cells; ANXA-1; Annexin A1; BRCA; Breast cancer susceptibility gene; CT; Cancer-testis; EGFR; Epidermal growth factor receptor; ELISA; Enzyme linked immunosorbent assay; HDR; Ho
Keywords: APCs; antigen presenting cells; ATP; adenosine triphosphate; BBB; blood brain barrier; BM; bone marrow; CB; cord blood; CNS; central nervous system; CSF; cerebrospinal fluid; DAMPs; danger associated molecular pattern molecules; DCs; dendritic cells; EAE;
Keywords: PMNs; polymorphonuclear leukocytes; TANs; Tumor associated neutrophils; N1; proinflammatory; N2; anti-inflammatory tumor-promoting neutrophils; ELA2; neutrophil elastase; MMP8; neutrophils collagenase; MMP9; neutrophils gelatinase B; ECM; extracellular ma
Keywords: PD-1; PD-L1; Pembrolizumab; Immune checkpoints; Gastric cancer
Keywords: Immunology; immunotherapy; heterogeneity; OSCC; PD-L1; survival; pathology;
Keywords: CRC; colorectal cancer; SNP; single nucleotide polymorphism; CNV; copy number variant; GWAS; genome-wide association studies; GO; gene ontology; BP; biological process; CAM; cell adhesion molecule; CIN; chromosomal instability; MSI; microsatellite instabi
Keywords: DC; dendritic cell; ER; endoplasmic reticulum; IDO; indoleamine 2,3-dioxygenase; IFN-γ; interferon gamma; iNOS; inducible nitric oxide synthase; IRE1α; inositol-requiring enzyme 1 alpha; MAPK; mitogen-activated protein kinase; PD1; programmed death 1; P
Keywords: Metastatic renal cell carcinoma; Clear cell renal cell carcinoma; Non-clear cell renal cell carcinoma; Precision medicine; Personalized medicine; Targeted therapy; TKI; mTOR; PD-1; PD-L1
Keywords: Anti-PD-1 antibody; Immunotherapy; Nivolumab; PD-L1; Second-line treatment;
Keywords: IC; immune checkpoint; ICB; immune checkpoint blocker; irAE; immune-related adverse event; NSCLC; non-small cell lung cancer; ORR; overall response rate; OS; overall survival; RCC; renal cell carcinoma; Neoplasms; Aged; Toxicity; Immunotherapy; Medical on
Keywords: anti-PD-L1 Ab; anti-PD-L1 antibody; DFS; disease-free survival; IHC; immunohistochemistry; OS; overall survival; PD-1; programmed death 1; PD-L1; programmed death ligand 1; WHO; World Health Organization;
Keywords: BRAF; diagnosis; immune blockade; immunochemistry; melanoma; pathology; PD-1; PD-L1; targeted therapy; therapy; TILs; treatment
Keywords: Unfolded protein response; Myeloid cells; T cells; Inflammation; Cell-nonautonomous; Tumor microenvironment; APC; antigen presenting cells; ATF6; activating transcription factor 6; CHOP; CCAAT/-enhancer binding protein homologous protein; DC; dendritic ce
Keywords: CTLA-4; PD-1; Prostate cancer; Kidney cancer; Bladder cancer; PD-L1; LAG-3
Keywords: PD-1; PD-L1; PD-L2; Lymphoid malignancies; Pidilizumab; Nivolumab; Pembrolizumab
Keywords: Ab; antibody; ACT; adoptive cell therapy; ANG; angiopoietin; ATP; adenosine triphosphate; BMDC; bone marrow derived cell; CA4P; combretastatin A phosphate; CAF; cancer-associated fibroblast; CCL2; C-C motif ligand 2; CD; cluster differentiation antigen; C
Keywords: TME; tumour microenvironment; MSC; mesenchymal stem cell; NK; natural killer; APC; antigen presenting cell; EC; endothelial cell; ECM; extracellular matrix; CAF; cancer-associated fibroblast; EMT; epithelial-mesenchymal transition; αSMA; alpha smooth m
Keywords: Colorectal cancer; Targeted therapy; Lynch syndrome; Microsatellite instability; Mismatch repair; EGFR pathway; Immune checkpoint blockade; PD-L1
Keywords: Melanoma; Liquid biopsy; Circulating tumor cells; Cell-free circulating tumor DNA; Cell-free DNA; Cell-free microRNA; Ab; antibody; AIM1; absent in melanoma-1; AJCC; American Joint Committee on Cancer; BRAF; B-Raf proto-oncogene, serine/threonine kinase;
Keywords: Inflammation; Tumor; Cancer; Chemokines; Cytokines; Exosomes; G-CSF; granulocyte colony-stimulating factor; HIF-1; hypoxia-inducible factor 1; IGF2; insulin-like growth factor 2; IL; interleukin; MCP-1; monocyte chemoattractant protein-1; MDSC; myeloid-de
Keywords: Liver; Immunity; Tolerance; Autoimmunity; Antigen presentation; Innate lymphocytes; AIH; autoimmune hepatitis; ALD; autoimmune liver disease; APC; antigen-presenting cell; CTLA-4; cytotoxic T cell antigen-4; DC; dendritic cell; α-GC; α-galactosylceramid